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Implication of an increased oxidative stress in the formation of
advanced glycation end products in patients with end-stage renal failure.
Recent studies have demonstrated a marked increase in the level of
advanced glycation end products (AGEs) in the plasma, skin and amyloid
fibrils of hemodialysis (HD) patients. The presence of AGEs in (/32m)
forming amyloid fibrils has been established in a previous immunochemi-
cal study relying on a monoclonal anti-AGE antibody. In the present
study, Western blot analysis and immunohistochemistry reveal that the
epitope recognized by this antibody is N-(carboxymethyl)lysine (CML)
and that CML is one of the AGE structures present in amyloid fibrils.
Thus, two AGE structures, CML and pentosidine, are now recognized in
dialysis-related amyloidosis. AGE accumulation in uremia is not ac-
counted for by elevated glucose levels. Since CML and pentosidine
formation are closely linked to oxidative processes, we tested the hypoth-
esis that a high oxidative stress enhanced AGE formation in HD patients.
We focused on ascorbic acid (AA) because AA is easily oxidized under
oxidative stress and its oxidized form (oxiAA) is a source of CML and
pentosidine. In vitro incubation of /32m with AA under atmospheric oxygen
resulted in: (1) the rapid appearance of characteristic physicochemical
properties of AGEs (brown color, fluorescence, polymerization tendency);(2) the transformation of 2m into AGE-modified 2m recognized by a
specific monoclonal antibody; and (3) the accelerated formation of CML
in 2m and p2m-peptide, recognized by mass spectrometry. A similar in
vitro incubation of human serum albumin disclosed a parallel production
of pentosidine measured by high-performance liquid chromatographic
assay. In HD patients, the degree of AA oxidation, assessed as the ratio of
oxiAA to total ascorbate, was more than twice as high as that of normal
subjects (0.87 0.16vs. 0.35 0.11, P < 0.0001), suggesting the presence
of an increased oxidative stress. Interestingly, plasma level of oxiAA was
correlated with the plasma levels of protein linked (P < 0.01, r2 = 0.25)
and free (P < 0.05, r2 = 0.22) pentosidine. Altogether these results
demonstrate that AGE, that is, CML and pentosidine, production is
accelerated under oxidative stress, even in the absence of glucose. They
suggest that, in uremia, CML and pentosidine production is determined
both by an increased oxidative stress and the availability of precursors such
as oxiAA. Finally, both CML and pentosidine contribute to the AGEs
present in dialysis-related amyloid fibrils.
Normal proteins are modified over the months by the non-
enzymatic Maillard reaction linking protein amino groups with
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glucose-derived aldehyde groups, and yield the so-called advanced
glycation end products (AGEs) [1, 21. AGE modified proteins
increase slowly with ageing and are thought to contribute to
normal tissue remodeling. Their level increases markedly in
diabetic patients [3—5 as a result of sustained hyperglycemia, and
lead to tissue damage through a variety of mechanisms including
alteration of tissue proteins structure and function [1, 4], stimu-
lation of cellular responses [6—12] through AGE specific receptors
[13—15], or the generation of reactive oxygen intermediates [16—
18]. However, the most dramatic rise in AGE levels is observed in
uremia irrespective of the presence or absence of diabetes [3, 19,
20]. It is associated with a variety of disorders not only analogous
to those observed in diabetes but also more specifically to
end-stage renal failure such as dialysis-related amyloidosis [21,
22]. Interestingly, AGE accumulation in uremia is not related to
hyperglycemia, therefore suggesting the presence in uremia of
serum of unknown precursor(s) or catalyst(s) [20].
Considerable evidence obtained in Vitro suggests that oxidative
stress accelerates AGE formation [16, 23—271. Chronic uremia
might be a state of increased oxidative stress, as suggested by
increased lipid peroxidation assessed by malondialdehyde [28, 29],
an increased ratio of oxidized glutathione to reduced glutathione
[30, 31], a decreased activity of glutathione-dependent enzymes
such as glutathione S-transferase, glutathione reductase and glu-
tathione peroxidase [31], and, more recently, elevated levels of
"advanced oxidation protein products" [321. The possibility that
oxidative stress contributed to elevated AGE levels in uremia was
thus evaluated in the present study. AGEs include a variety of
structures. We previously identified pentosidine [33] as a native
structure for AGEs in dialysis-related amyloidosis [22]. We now
extend this observation to N-(carboxymethyl)lysine (CML), an-
other AGE structure reactive with anti-AGE antibody [34]. We
further demonstrate that, in vitro, atmospheric oxygen taken as an
oxidative stress accelerated, within a short incubation period, the
production of pentosidine and CML from ascorbate but not from
glucose. Finally, we report that in patients undergoing chronic HD
the ratio of oxidized form of ascorbic acid to total ascorbate is
increased, which is evidence taken to indicate an oxidative stress.
Under those circumstances, there is a linear relationship between
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the plasma levels of oxidized ascorbate and those of both protein-
linked and free-form pentosidine. This relationship is absent in
healthy individuals. This observation is taken as evidence that
pentosidine and CML formation are enhanced by the oxidative
stress of uremia and that, under these circumstances, oxidized
ascorbate might be a precursor of both AGE structures.
Methods
Synthesis of CML and pentosidine
To synthesize CML, a solution of 32 mmol of t-butyl bromoac-
etate in 10 ml of tetrahydrofuran was added dropwise to a stirred
mixture of 26.7 mmol of N-t-hutoxycarbonyl-L-lysine methyl
ester and 26.7 mmol of triethylamine in 400 ml of tetrahydrofuran.
The reaction mixture was stirred at room temperature for 15
hours, filtered to remove the precipitates, and concentrated in
vacuo. The residue was then dissolved in ethyl acetate, washed
with distilled water, concentrated in vacua, and further purified by
silica gel column chromatography using 5/95 methanol/chloro-
form (vol/vol) to give N'°-t-hutoxycarbonyl-N-(carboxymethy1)-L-
lysine methyl ester. The obtained product (2.32 g) was hydrolyzed
in 100 ml of 6 N HCI for three hours, lyophilized, and dissolved in
distilled water. Pentosidine was prepared according to our previ-
ous method [20]. The identity of the final product was confirmed
as CML and pentosidine by nuclear magnetic resonance and fast
atom bombardment (FAB)-mass spectrometry (MS).
Sample preparation
Human normal and acidic isoforms of /32-microglobulin (/32m)
were purified from the urine of long-term HD patients who were
free of urinary infection, as described previously [21]. A peptide
(Ile-Gln-Arg-Thr-Pro-Gly-Ile, peptide-1), corresponding to the
amino terminal seven amino acid residues except for glycine-6
instead of lysine-6, was synthesized by a peptide synthesizer model
432A (Applied BioSystems).
Purified normal l32m (50 xg) or the synthesized peptide (10 xg)
was incubated under atmospheric oxygen at 37°C for several
durations with various concentrations of either D-glucose (Wako
Pure Chemicals, Tokyo, Japan) or ascorbic acid (AA; Wako Pure
Chemicals), or both of them in 50 pA of 0.1 M sodium phosphate
buffer (pH 7.4) containing 1 mvt diethylenetriaminepentaacetic
acid (DTPA; Sigma Chemical Co., St. Louis, MO, USA). Upon
incubation under atmospheric oxygen, AA is easily converted into
its oxidized form, dehydroascorbic acid (DHA). In some experi-
ments, incubation was performed in the presence of 40 mrvi
sodium cyanoborohydride (NaBH1CN; Sigma), which reduces the
Schiff base and prevents Amadori rearrangement, or in the
presence of DHA (Sigma) instead of AA. After incubation, the
samples underwent high-performance liquid chromatography
(HPLC; model LC-1OA; Shimadzu, Kyoto, Japan) on a C18
reverse-phase column (Waters, Tokyo, Japan), and the /32m or
peptide fraction was collected.
To prepare /32m or bovine serum albumin (BSA) modified with
pentosidine (pentosidine-/32m or -BSA) or CML (CML-132m or
-BSA), synthesized pentosidine or CML were conjugated with
f32m or BSA (essentially fatty acid-free grade; Sigma) according to
our previous method [22]. Briefly, 2.0 mg of normal /32m or BSA
was incubated with 4.3 xmol of CML or 4.3 .tmol of pentosidine
in the presence of 0.03 mmol of 1-ethyl-3-(3-dimethylaminopro-
pyl) carbodiimide-HCI (Pierce) and 0.4 mg of N-hydroxysulfosuc-
cinimide (Pierce) in 3 ml of phosphate buffered saline (PBS) for
four hours at room temperature and then overnight at 4°C. BSA
modified with pyrraline was kindly provided from Dr. Satoshi
Miyata.
To examine pentosidine generation, 30 mg of human serum
albumin (HSA; essentially fatty acid-free grade; Sigma) was
incubated at 37°C with either 100 ifiM glucose, AA, or D-ribose
(Sigma) in 1.0 ml of 0.1 M sodium phosphate buffer (pH 7.4) under
atmospheric oxygen, and the level of pentosidine was determined
at intervals by HPLC assay after acid hydrolysis as described
below.
Immunoblot analysis
The samples (10 xg each) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a
15% acrylamide gel for /32m and a 5 to 20% gradient gel for BSA.
After electrophoretical transfer to a polyvinylidene difluoride
membrane (Bio-Rad, Hercules, CA, USA), the membrane was
incubated with 3% skim milk overnight, and reacted for one hour
at room temperature with anti-AGE mouse monoclonal IgG,
6D12 (10 xg/ml) [35] in the buffer containing 25 mM Tris-HCI (pH
7.5) and 0.5 M NaCI, followed by three-time washings with the
same buffer containing 0.1% Tween-20. The membrane was then
incubated with 1:3,000 diluted goat anti-mouse IgG conjugated
with alkaline phosphatase (Organon Teknika) for one hour at
room temperature, washed three times, and reacted with 5-bro-
mo-4-chloro-3-indolyl phosphate (0.15 mg/mI) and nitroblue tet-
razolium (0.30 mg/ml) solution (Gibco, Gaithersburg, MD, USA)
in the buffer containing 0.1 M Tris-HC1 (pH 9.5), 0.1 M NaCl, 50
mM MgC12 until specific bands became clear. For competition
experiments to confirm the specificity of immunostaining, the
anti-AGE antibody was preincubated with 50 jxg of CML-BSA for
three hours at 37°C and used for the experiments. Non-immune
mouse IgG was used as a negative control.
Immunohistochemistty
Amyloid tissues were obtained at autopsy from patients with
long-term HD patients who had undergone HD for more than ten
years. The specimens were fixed in 10% formalin and embedded
in paraffin. Specimens positive for Congo red staining were
subjected to indirect immunohistochemical staining. In brief,
sections cut at 2 jxm were mounted on slides coated with
3-aminopropyltriethoxy silane (Sigma), deparaffined, rehydrated
in distilled water, and then incubated with Pronase (0.5 mg/ml;
Dako, Glostrup, Denmark) in buffer containing 0,05 M Tris-HC1
(pH 7.2) and 0.1 M NaCI for 15 minutes at room temperature. The
sections were washed with PBS containing 0.5% Tween and
blocked in 4% skim milk for two hours. The sections were then
incubated with either anti-AGE mouse monoclonal IgG (10
g/ml) or anti-f32m rabbit IgG (10 xg/ml; Dako, Glostrup, Den-
mark) overnight in humid chambers at room temperature. The
sections were washed and incubated with 1:500 diluted goat
anti-mouse or rabbit IgG conjugated with alkaline phosphatase
(Dako) for two hours at room temperature, followed by the
detection with 5-bromo-4-chloro-3-indolyl phosphate and ni-
troblue tetrazolium solution. Competition experiments were per-
formed using the anti-AGE antibody preincubated with CML-
BSA. Non-immune mouse JgG was used as a negative control.
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Fluorospectrometry
Protein-bound fluorescence was analyzed in a fluorescence
spectrophotometer (model RF540; Shimadzu, Kyoto, Japan) at a
protein concentration of 0.2 mg/mi in 10 mM sodium phosphate
buffer (pH 7.2).
Protein digestion with endoproteinase Lys-C (Endo Lys-C)
To digest the sample into peptides for MS, normal 2m,
glycated f32m, and CML-132m (100 sg each) were reacted with 5
xg of Endo Lys-C (Acromobacter Protease I; Wako Pure Chem-
icals) at 37°C for eight hours as described previously [36]. The
digested peptides were separated on a HPLC system using a C18
reverse-phase column, detected by their absorbance at 214 nm,
collected, and then subjected to MS and peptide sequencing on an
automatic protein sequencer (model 473A gas-phase sequencer;
Applied Biosystems, Foster City, CA, USA).
MS
A sector-type mass spectrometer JMS SX1O2A (JEOL, Ak-
ishima, Japan) was used for electrospray ionization (ES!) and fast
atom bombardment (FAB) MS as described previously [361. For
ESI-MS, samples were dissolved in a solvent of 49/49/2 methanoi/
H20/acetic acid (vol/vol/vol) at a protein concentration of 10 ISM.
An aliquot (20 sl) of the sample solution was directly introduced
into the ES! ion source at a flow-rate of 0.8 si/min with a syringe
pump (Harvard Apparatus, Woburn, MA, USA). For FAB-MS, a
few hundred nanomoles of sample was dissolved in 10 jd of
glycerol as sample matrix, and bombarded with Xe atoms from a
FAB gun. The instrument employed for matrix-assisted laser
desorption time-of-flight (MALDITOF) MS was Vision 2000
(Finnigun MAT, Hemel Hempstead, UK). The sample (10 sM)
was mixed with the matrix 2,5-dihydroxybenzoic acid (10 mg/mi)
in a volume ratio of 1:1. Subsequently, 1 d of the solution was
dried on the target, and then ionized with a N2 laser beam. In this
study, monoisotopic mass was used for FAB-MS, and chemical
mass was used for ESI- and MALDITOF-MS.
Pentosidine measurement by HPLC assay
Fresh heparinized plasma samples were obtained with informed
consent from 24 non-diabetic HD patients (13 males and 11
females, age range 41 to 85 years old, HD duration range 4 to 18
years). HD was performed with a cuprophane dialyzer and
diaiysate containing 30 mmol/liter of bicarbonate and 8 mmol/Iiter
of acetate. The plasma protein concentration was determined
using a kit (Bio-Rad) with HSA as a standard. Plasma pentosidine
is known to exist either in protein-linked form or in free-form [20].
For quantitation of total pentosidine, plasma was lyophilized,
hydrolyzed by 100 sl of 6 N HCI for 16 hours at 110°C under
nitrogen, followed by neutralization with 100 1d of 5 N NaOH and
200 sl of 0.5 M sodium phosphate buffer (pH 7.4), filtered through
a 0.5 m filter, and diluted with PBS. For quantitation of free
pentosidine, the plasma was mixed with an equal volume of 10%
TCA, centrifuged at 5000 x g for 10 minutes, filtered through a
0.5 xm filter, and diluted with PBS. Pentosidine in these speci-
mens was quantitated by HPLC assay as described previously [201.
Briefly, a 50 jsl solution of plasma acid hydrolysate (corresponding
to 25 sg of plasma proteins) or diluted protein-free plasma
(corresponding to 6.25 sl of plasma) was injected into an HPLC
system and separated on a C18 reverse-phase column. The
effluent was monitored at an excitation-emission wavelength of
335/385 nm using a fluorescence detector (RF-IOA; Shimadzu).
Synthetic pentosidine was used to obtain a standard curve. The
substance in the specimens, detected at the same retention time as
authentic pentosidine, was confirmed as pentosidine by FAB-MS.
The protein-linked pentosidine level was calculated as: protein-
linked pentosidine (pmol/mg) = [total pentosidine (pmol/ml)-free
pentosidine (pmol/ml)]/protein concentration (mg/mi). Plasma
protein-linked and free pentosidine levels were expressed as pmol
per mg of protein and pmol per ml of plasma, respectively. Limits
of detection were 0.05 pmol/mg for protein-linked pentosidine
and 4 pmol/ml for free pentosidine.
Ascorbate measurement
The levels of AA and its oxidized form (oxiAA), that is, DI-IA
and 2,3-diketogulonic acid, were measured in the same fresh
plasma samples of HD patients described above and in 16 healthy
individuals (10 males and 6 females, age range 28 to 61 years old),
according to the method of Roe et a! [37]. Neither patients nor
healthy controls were given ascorbate therapy. In this method, the
level of total ascorbate (AA plus oxiAA) or oxiAA can be
measured. For determination of the level of total ascorbate, a 180
d sample of plasma was mixed in an eppendorf tube with 320 pi
of distilled water, 20 1id of 0.2% indophenol, and 60 pi of 30%
HPO3, and, after three minutes, with 40 sl of 24% SnCl2, 60 xl of
30% HPO3, and 40 1.d of 0.1% dithiothreitol. For determination
of the oxiAA level, a 180 d sample of plasma was mixed in an
eppendorf tube with 340 1d of distilled water, 40 d of 24% SnCl2,
120 ud of 30% HPO3, and 40 jxl of 0.1% dithiothreitol. These
mixtures were kept on ice for 10 minutes and centrifuged at
15,000 >< g for 10 minutes. The supernatant (100 pA) was
transferred to a well of a 96-well plate, mixed with 25 jsl of
2,4-dinitrophenylhydrazine, and incubated for three hours at
37°C. The mixture was then put on ice, added with 125 pA of 85%
H2S04, and kept on ice for 10 minutes. The plate was kept for 30
minutes at room temperature and the absorbance at 540 nm was
measured by a microplate leader (model 450; Bio-Rad). AA
(Wako Pure Chemical) was used to obtain a standard curve.
Statistical analysis
Data are expressed as means sn. Student's t-test was used for
a statistical evaluation of significant difference between the two
groups. Correlation was assessed by linear regression analysis.
Results
Identification of CML as one of the AGE structures in amyloid
fibrils
On immunoblot analysis (Fig. 1), the anti-AGE mouse mono-
clonal antibody reacted with AGE-proteins prepared in vitro, such
as AGE-132m (lane 3), AGE-BSA (lane 10), and AGE-keyhole
limpet hemocyanin (KLH; data not shown), but not with their
normal counterparts (lanes 1 and 9) nor Amadori compound
(lane 2). When the immunoreactivity of this antibody was exam-
ined using several AGE structures postulated so far, the antibody
recognized proteins modified with CML (lanes 5 and 12), but not
with pentosidine (lanes 6 and 13) or pyrraline (lane 14), indicating
that the epitope structure of this antibody is CML. In fact,
MALDITOF-MS of digested peptides generated by Endo Lys-C
cleavage of 2m demonstrated carboxymethylation of the amino
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Fig. 1. Identification of CML as an epitope-stmcture of the monoclonal anti-A GE antibody. The protein (A, 132m; B, BSA) was resolved by SDS-PAGE,
followed by Western blotting using the monoclonal anti-AGE antibody used in our previous study [21]. A. Lane 1, normal f32m; lane 2, 2m upon
incubation with 100 mi glucose for 10 days (Amadori-132m); lane 3, 132m upon incubation with 100 m glucose for 70 days (AGE-/32m); lane 4, f32m
upon incubation with 20 mvi AA in the presence of NaBH3CN for 15 hours; lanes 5, 7 and 8, CML-2m; lane 6, pentosidine-/32m. B. Lane 9, normal
BSA; lane 10, BSA upon incubation with 100 m glucose for 60 days (AGE-BSA); lane 11, BSA upon incubation with 20 mM AA in the presence of
NaBH3CN for 15 hours; lane 12, CML-BSA; lane 13, pentosidine-BSA; lane 14, pyrraline-BSA. The samples were prepared as described in the Methods
section. The antibody preincubated with an excess of CML-BSA was used for the competition experiment (lane 7). Non-immune mouse IgG was used
as a negative control (lane 8). The positions of 2m and BSA (arrows) and migration of standard proteins are indicated.
terminal peptide from AGE-/32m (Fig. 2C) and CML-2m (Fig.
2D), and both of which reacted with the antibody, whereas no
carboxymethylation was detected in normal 132m (Fig. 2A), Ama-
dori-/32m (Fig. 2B), or pentosidine-132m (data not shown), none of
which reacted with the antibody. The immunoreactivity of the
anti-AGE antibody was completely abolished after preincubation
with CML-BSA (lane 7) as well as AGE-BSA (data not shown),
reflecting a high specificity of the immunoreaction of the anti-
body. No immunoreaction was detected with non-immune mouse
IgG (lane 8). Together with our previous observation that amyloid
fibril proteins isolated from patients with dialysis-related amyloid-
osis reacted with this anti-AGE antibody [21], these findings
indicate that CML is one of AGE structures in amyloid fibrils of
dialysis-related amyloidosis.
The presence of CML was further identified in amyloid deposits
by immunohistochemistry. Massive deposits, surrounded with
tissue macrophages, stained positive for Congo red with green
birefringence under polarized light (data not shown) and for /32m
(Fig. 3A), indicating that these were /32m-amyloid deposits. The
same deposits reacted with the monoclonal anti-AGE antibody
(Fig. 3B), in good agreement with our previous results [22].
Pre-adsorption of the anti-AGE antibody with CML-BSA (Fig.
3C) and AGE-BSA as well (data not shown) abolished the
immunostaining. Non-immune mouse IgG gave no immunostain-
ing pattern (data not shown).
Appearance of characteristic physicochemical properties of AGEs
in /32m upon incubation with ascorbate
When normal 132m was incubated for 7 or 21 days with AA or
DHA in vitro under atmospheric oxygen, 2m turned brown and a
major portion of 2m shifted its electrophoretic mobility on
two-dimensional PAGE to an acidic position (data not shown)
similar to that of acidic f32m, a major isoform of f32m recognized
in amyloid fibrils as well as in 2m modified with AGEs [21]. In
addition, incubation of f32m with ascorbate resulted in the forma-
tion of high-molecular-weight protein aggregates on SDS-PAGE
(data not shown).
The protein-bound fluorescence of dialyzed materials from the
reaction mixture was then analyzed by fluorospectrometer. Upon
incubation with AA (Fig. 4, line 5, 7 days; line 6, 21 days) or DHA
(line 7, 7 days; line 8, 21 days), the /32m exhibited fluorescence
spectra similar to those of acidic f32m (line 2) and normal f32m
incubated with glucose for 42 days, that is, in vitro-prepared
AGE-132m (line 4). The fluorescence peak exhibited an emission
maximum at 430 to 450 nm upon excitation at 350 nm and an
excitation maximum at 340 to 360 nm upon emission at 450 nm.
These findings indicate that incubation of normal /32m with
ascorhate endows f32m with physicochemical properties of AGEs
indistinguishable from those of acidic !32m or in vitro-prepared
AGE-2m, that is, brown color, fluorescence, electrophoretical
shift to an acidic position, and polymerization tendency.
Formation of CML and pentosidine in /32m upon incubation with
ascorbate
When f32m was incubated with glucose and analyzed by ES I-MS
(Fig. 5B), a significant peak (AM) was detected in addition to a
peak (N) corresponding to normal f32m (Fig. 5A). The difference
in the molecular mass from peak N to peak AM was exactly 164
Da, indicating that this peak corresponds to the /32m with one
Amadori product [N-( 1-deoxyfructosyl)group]. However, no peak
corresponding to the 132m with CML (an increase of 58 Da in the
molecular mass) was detected in the ESI mass spectrum. By
contrast, when 2m was incubated with AA (Fig. 5C) and DHA
(data not shown), a peak of carboxymethylated /32m (peak CML)
appeared in the ESI mass spectrum. When /32m was incubated for
15 hours with glucose and AA, both peak AM and CML were
identified in the mass spectrum (Fig. 5D). Changing the ratio of
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Fig. 2. MALDITOF mass spectra of the amino
terminal peptide generated by Endo-Lys C
digestion of normal f32m (A), f3,m upon
incubation with 100 mivi glucose for 10 days
(Amadori-132m; B) and 60 days (AGE-132m; C),
and j3,m modified with CML (CML-f3m; D).
The sample was digested with Endo-Lys C and
the peptides were separated by reverse-phase
HPLC. The peptide corresponding to the amino
terminal peptide (Ile-Gln-Arg-Thr-Pro-Lys, mol
wt 742) was collected and subjected to
MALDITOF-MS. Peptides were detected as
protonated molecular ion species at m/z 743, at
m/z 905, and m/z 801 for intact peptide (N),
peptide with an Amadori product (AM), and
carboxymethylated peptide (CML), respectively.
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Fig. 3. Immunohistochemical demonstration of CML in 132m amyloid deposits. Tissue sections of subcutaneous tumor containing amyloid deposits
obtained from a 37-year-old man undergoing HD for 18 years, were stained with anti-p2m antibody (A) and the monoclonal anti-AGE antibody (B and
C). The anti-AGE antibody preincubated with an excess of CML-BSA was used for the competition experiment (C) (X200). Publication of this figure
in color was made possible by a grant from Baxter Healthcare Corporation, McGaw Park, Illinois, USA.
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Fig. 4. Fluorescence spectra of normal /32m and
acidic (32m purified from urine of long-term HD
patients (A), and J32m incubated with glucose (A)
or ascorbate (B). Spectra obtained upon
excitation at 350 nm (left) and the excitation
spectra for emission at 450 nm (right) were
measured. Normal 132m (lane 1) and acidic 2m
(lane 2) purified from long-term HD patients;
f32m incubated with 100 m glucose for 14 days
(line 3) or 42 days (line 4); /32m incubated with
20 mri AA for seven days (line 5) or 21 days
(line 6), or with 20 mi DHA for seven days
(line 7) or 21 days (line 8).
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Fig. 5. Transformed ESI mass spectra of 132m
incubated with glucose and/or ascorbate. Normal
132m was incubated at 37°C for 15 hours with 50
mM glucose and/or 2 mi AA in the presence of
NaBH1CN, purified by reverse-phase HPLC,
and subjected to ESI-MS. A. Normal 2m. B.
/32m incubated with glucose. C. 132m incubated
with AA. D. 2m incubated simultaneously with
glucose and AA. Abbreviations are: N, intact
2m (11729 Da); AM, the 2m with one
reduced Amadori product derived from glucose
(11893 Da); CML, the f32m with one
carboxymethylation (11787 Da). In this
experiment, NaBH3CN was used because
otherwise the ESI mass spectrum of the 2m
incubated with AA showed vety heterogeneous
clusters of protein molecules from
fragmentation and cross-linking due to
advanced glycoxidation reaction.
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glucose and AA concentrations resulted in a correlative change of
the ratio between the two peaks (data not shown).
Since the primary site of the Maillard reaction in /32m is the
a-amino group of the amino terminal isoleucine [36], a synthetic
peptide-1 (Ile-Gln-Arg-Thr-Pro-GIy-IIe; mol wt 783.5) having the
same amino terminal sequence as human f32m, except for a
substitution of glycine for lysine at the 6th position, was incubated
with ascorbate and analyzed by FAB-MS. FAB-MS of the authen-
tic peptide identified a single peak at mlz 784.5 Da, exactly
corresponding to the mass for the protonated ion of this peptide
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1000 Fig. 6. FAB mass spectra of the synthetic 13m
peptide incubated with glucose and/or ascorbate.
A synthetic peptide, peptide-1 (Ile-Gln-Arg-
Thr-Pro-Gly-Ile, mol wt 783.5), was incubated
at 37°C for 15 hours with 50 mM glucose and/or
2 m'vi AA in the presence of NaBH3CN,
purified by reverse-phase HPLC, and subjected
to FAB-MS. A. Peptide-l incubated with
glucose. B. Peptide-l incubted with AA. C and
D. Peptide-1 incubated simultaneously with 50
mM glucose and AA (C, 2 mM; D, 4 mM).
Peptides were detected as protonated molecular
ion species at m/z 784.5, at m/z 948.5, and at
m/z 842.5 for intact peptide-1 (N), peptide-1
with an Amadori product in reduced form
(AM), and carboxymethylated peptide-1
1000 (CML), respectively. NaBH3CN was used in
this experiment (see legend of Fig. 5).
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Fig. 7. Formation of pentosidine upon incubation with glucose, ascorbate,
or ribose. HSA (30 mg) was incubated at 37°C with either 100 m glucose,
AA, or ribose in 0.1 M phosphate buffer (pH 7.4), Pentosidine level was
determined at intervals by HPLC assay after acid hydrolysis 20]. Symbols
are: () glucose; (S) AA. The pentosidine level in HSA upon incubation
with ribose was 1250 pmol/mg at one week.
(data not shown). Both glucose and AA are capable of forming a
covalent adduct with this peptide in a concentration-dependent
manner, leading to addition of an adduct of 164 Da and 58 Da,
respectively (Figs. 6 A, B). When peptide-1 was incubated simul-
taneously with glucose and AA, both peak AM and CML were
identified in the mass spectrum (Fig. 6C). Changing the ratio of
glucose and AA concentrations resulted in a correlative change of
the ratio between the two peaks (Fig. oD).
The contention that ascorbate initiates the glycoxidation reac-
tion with proteins and forms CML was further supported by the
result of Western blot analysis (Fig. 1). Upon incubation with AA
under atmospheric oxygen, both 2m (lane 4) and BSA (lane 11)
reacted with the monoclonal anti-AGE antibody.
To know whether pentosidine, another AGE structure in
amyloid fibrils of patients with dialysis-related amyloidosis [22], is
also formed in the presence of ascorbate, HSA was incubated with
either ribose, glucose, or AA, and the amount of pentosidine
generated was determined by HPLC assay (Fig. 7). Upon incuba-
tion with ribose, a well-known source of pentosidine, HSA formed
brown aggregates for a short duration, indicating accelerated
pentosidine formation. Although both glucose and AA could be a
source of pentosidine, the rate of pentosidine formation with AA
(47.6 pmol!mg of HSAJweek in this condition) is about ten times
faster than that with glucose (4.8 prnol/mg!week).
Increased ascorbate oxidation in HD patients
Plasma ascorbate level was measured in non-diabetic HD
patients. Total ascorbate levels were markedly lower (P < 0.0001)
in HD patients (4.51 2.84 jig/mI) than in normal individuals
(10.23 3.09 jig/mI), in good agreement with a previous report
[28]. By contrast, the ratio of oxiAA to total ascorbate, was much
higher (P < 0.0001) in HD patients (0.87 0.16) than that in
normal subjects (0.35 0.11; Fig. 8A). If the ratio of oxiAA to
total ascorhate is taken as a marker of the redox state, this finding
indicates a significantly higher oxidative stress in HD patients than
in normal subjects.
OxiAA is one of the reactive species for the Maillard reaction
with AA [24, 25, 38—40]. Interestingly, its serum level in HD
patients is significantly correlated with protein-linked pentosidine
(P < 0.01) and with free-form pentosidine (P < 0.05; Fig. 8B). No
such correlation is observed in normal subjects despite a similar
range of oxiAA serum levels.
Discussion
In the first part of this paper, we demonstrate that CML is a
native structure of AGEs in f32ni amyloid deposits of patients on
HD. This observation, taken together with our recent identifica-
tion of pentosidine in similar dialysis-related amyloidosis deposits
[22], establishes the variety of molecular structures developed as a
result of advanced glycation in uremia. Both epitopes have also
been recognized in the skin collagen of non-uremic diabetic
patients [5]. Recognition of such specific molecular motives in
amyloid deposits should help unravel the mechanisms of dialysis-
related amyloidosis. Both pentosidine and CML are useful bio-
markers of the cumulative protein damage induced by glycoxida-
tion [16, 25]. Their presence in amyloid fibrils suggests a potential
link between oxidative stress and the development of dialysis-
related amyloidosis.
Simultaneously, we demonstrate that the monoclonal anti-AGE
antibody [35] utilized in this and in a previous study [21],
recognizes only CML, but neither pentosidine nor pyralline, which
are other AGE structures. Reddy et al [34] also found recently
that the major epitope of their polyclonal anti-AGE antibody was
CML. Our own polyclonal anti-AGE antibody raised by immuni-
zation with AGE-KLH reacted with proteins (BSA, 2m, and
KLH) modified with CML, but not with their counterparts
modified with pentosidine nor pyrraline (our unpublished obser-
vation). These findings support the assumption by Baynes and
colleagues that AGEs are largely glycoxidation products, and that
CML is a major antigenic determinant in AGE-proteins. In fact,
the amount of CML was shown to be approximately 40 to 70 times
higher than that of pentosidine in skin collagen of diabetic
patients [5].
AGE accumulation is enhanced in diabetes as a result of
sustained hyperglycemia. In uremia by contrast, despite an even
more striking rise in the serum levels of AGEs including pento-
sidine, glucose levels are normal. We, therefore, postulated the
existence in uremia of factors either producing unknown precur-
sor(s) or catalyzing the formation of AGEs. In the second part of
this work, we now provide evidence suggesting that AGE accu-
mulation including pentosidine and CML is linked in uremia to a
redox imbalance.
The formation of advanced glycoxidation products has been
closely linked to oxidation processes. Wolff et al demonstrated
that reducing sugars can autoxidize by metal-catalyzed oxidative
processes and generate H202, reactive oxygen intermediates, and
ketoaldehydes, which contribute to chromo- and fluorophoric
alterations of proteins [26, 27]. Ahmed, Thorpe and Baynes
showed that CML is formed on oxidative degradation of fructose-
lysine [23] and also by reaction with autoxidative products of
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ascorbate [241 and glucose [41]. They further demonstrated that
oxidation is an essential process in the formation of pentosidine
[25]. These findings indicate that AGEs are products of the
combined processes of glycation and oxidation.
The hypothesis that an increased oxidative stress contributes to
the generation of AGEs in uremia is supported by both our in vitro
and in vivo observations. In vitro, the incubation of 132m or HSA
with ascorbate, under oxidative stress of atmospheric oxygen,
leads to the accelerated formation of AGEs, and more specifically
CML and pentosidine, whether or not glucose is present in the
medium. The appearance of AGEs in the medium was established
first by the detection within 7 to 21 days of !32m modifications
indistinguishable from those of acidic and in vitro-prepared AGE-
f32m, that is, brown color, fluorescence, electrophoretical shift to
an acidic position and polymerization tendency, and second by a
specific recognition by a monoclonal anti-AGE antibody. A more
detailed analysis by ESI-MS reveals the prompt appearance,
within 15 hours, of the specific AGE structure, CML. CML
formation was further located mainly to the amino terminal seven
amino acid residue of 132m; when this synthesized peptide was
incubated under the same condition as whole 2m, CML was
detected by FAB mass spectra within the same time span.
Pentosidine also was generated at an accelerated rate as demon-
strated by the incubation of HSA under similar conditions. AGE
production was markedly accelerated under oxidative stress only
in the presence of ascorbate, a reducing substance, precursor of
both pentosidine and CML [24, 25, 40]. Neither CML nor
pentosidine generation was accelerated when only glucose was
present in the incubation medium. These observations suggest
that the oxidative stress contributes to AGE formation only in the
presence of precursors. This conclusion is further supported by in
vitro evidence that the absence of oxygen in the incubation
medium prevents the ascorbate-induced enhancement of CML
and pentosidine production [23, 25].
Fig. 8. Plasma levels of oxiAA in non-diabetic
HD patients. A. The degree of conversion of
AA into oxiAA in HD patients (N = 24) and
normal subjects (N = 16). Plasma levels of AA
and oxiAA were determined and the ratio of
oxiAA to total ascorbate (AA plus oxiAA) is
shown as the mean SD. P < 0.0001 versus
normal subjects. B. Correlation between
pentosidinc, measured by HPLC assay, and
oxiAA in the plasma of HD patients. There was
a positive correlation between protein-linked
pentosidine and oxiAA (upper panel: N = 24,
P < 0.01, r = 0.25), and between free
pentosidine and oxiAA (lower panel: N = 24,
P < 0.05, 2 = 0.22). The equation of the line
for protein-linked pentosidine is y 29.4x +
8.2; and for free-form pentosidine is y = 61.8x
+ 24.7.
In vivo observations provide further insights into the generation
of AGEs in uremic subjects. The ratio of oxiAA to total ascorbate
is markedly increased above normal in patients given chronic HD,
suggesting that uremia is associated with increased oxidative
stress. The existence of a redox imbalance in chronic uremia is
supported by several lines of evidence such as an increased lipid
peroxidation [28, 29], an increased ratio of oxidized to reduced
glutathione [30, 31], a decreased activity of glutathione-dependent
enzymes [31], and, more recently, an elevated level of "advanced
oxidation protein products" [32].
However, the most interesting result of the in vivo observations
is the demonstration of a correlation between the plasma concen-
tration of oxiAA and both protein-linked and free levels of
pentosidine. The plasma levels of oxiAA in our patients are within
the normal range (0.36 2.84 vs. 0.34 0.12 jxglml in normals)
as a result of both a reduced concentration of total ascorbate, a
well known feature of chronic uremia [28] and the augmented
oxiAA/total AA ratio. This correlation, absent in normal subjects,
suggests that oxiAA level is a rate limiting precursor of AGEs, in
this case pentosidine, only under conditions of oxidative stress. Of
note, Dyer et al [25] raised this hypothesis on the basis of in vitro
studies.
Witko-Sarsat et al [32] have recently described a similar rela-
tionship between the serum levels of pentosidine and "advanced
oxidation protein products" (taken as highly oxidized proteins) in
normal subjects and HD patients. These results were interpreted
as evidence that both "advanced oxidation protein products" and
pentosidine levels are determined by the intensity of the prevail-
ing oxidative stress. The oxiAA-pentosidine relationship observed
in our HD patients does not fit this hypothesis as we found no
correlation between the intensity of the oxidative stress, assessed
by the ratio of oxiAA to total ascorbate, and pentosidine. This
tentative conclusion will need confirmation by other methods
evaluating the severity of the oxidative stress.
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Finally, it should be pointed out that although pentosidine and
CML are clearly markers of AGEs in dialysis-related amyloidosis,
neither of these structures appears able to induce monocyte
chemotaxis and macrophage secretion of cytokines [10 and our
unpublished data]. Taken together with the fact that other AGE
structures, such as 2-(2-furoyl)-4 [5]-(2-furamyl)-IH-imidazole
(FF1) [42], pyralline [43] and their BSA conjugates, exhibit no
ligand activity for the AGE receptor of peritoneal macrophage
[35, 44], these data demonstrate that another, as yet unidentified,
AGE structure is responsible for the biological activity towards
monocytes/macrophages [6—I 0, 14, 15]. If the same factors govern
the production of the various AGE structures, CML and pento-
sidine might prove adequate surrogate markers for this biologi-
cally active AGE structure.
To summarize, our results have identified both CML and
pentosidine as specific AGE structures present in dialysis-related
amyloid deposits. They further suggest that, in uremia, CML and
pentosidine production is determined both by an increased oxi-
dative stress and the availability of precursors among which oxiAA
and ribose have been identified.
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Appendix
Abbreviations used in this paper are: AGEs, advanced glycation end
products; AA, ascorbic acid; f32-microglobulin, 132m; BSA, bovine serum
albumin; CML, N-(carboxymethy1)1ysine; DHA, dehydroascorbic acid;
ESI, electrospray ionization; FAB, fast atom bombardment; HD, hemo-
dialysis; HPLC, high-performance liquid chromatography; HSA, human
serum albumin; keyhole limpet hemocyanin, KLH; matrix-assisted laser
desorption time-of-flight, MALDITOF; MS, mass spectrometry;
NaBH3CN, sodium cyanoborohydride; oxiAA, oxidized form of ascorbic
acid; PBS, phosphate buffered saline.
The term ascorbate is used instead of the abbreviations AA and oxiAA
to refer in a general sense to both AA and oxiAA.
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